Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction

56Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aims Next to left ventricular (LV) hypertrophy, hypertrophic cardiomyopathy (HCM) is characterized by microvascular dysfunction and reduced myocardial external efficiency (MEE). Insights into the presence of these abnormalities as early markers of disease are of clinical importance in risk stratification, and development of therapeutic approaches. Therefore, the aim was to investigate myocardial perfusion and energetics in genotype-positive, phenotype-negative HCM subjects (carriers). Methods and resultsFifteen carriers of an MYBPC3 mutation underwent [ 15O]water positron emission tomography (PET) to assess myocardial blood flow (MBF). [ 11C]acetate PET was performed to obtain myocardial oxygen consumption (MVO2). By use of cardiovascular magnetic resonance imaging, LV volumes and mass were defined to calculate MEE, i.e. the ratio between external work and MVO2. Eleven healthy, genotype-negative, family relatives underwent similar scanning protocols to serve as a control group. Left ventricular mass was comparable between carriers and controls (93 ± 25 vs. 99 ± 21 g, P 0.85), as was MBF at rest (1.19 ± 0.34 vs. 1.18 ± 0.32 mL min -1 g -1, P 0.92), and during hyperaemia (3.87 ± 0.75 vs. 3.96 ± 0.86 mL min -1 g -1, P 0.77). Myocardial oxygen consumption averaged 0.137 ± 0.057 mL min -1 g -1 in carriers and was not significantly different from controls (0.125 ± 0.043 mL min -1 g -1, P 0.29). Cardiac work, however, was slightly reduced in carriers (7398 ± 1384 vs. 9139 ± 2484 mmHg mL in controls, P 0.08). As a consequence, MEE was significantly decreased in carriers (27 ± 10 vs. 36 ± 8 in controls, P 0.02). ConclusionCarriers display reduced myocardial work generation in relation to oxygen consumption, in the absence of hypertrophy and flow abnormalities. Hence, impaired myocardial energetics may constitute a primary component of HCM pathogenesis. © 2011 The Author.

Cite

CITATION STYLE

APA

Timmer, S. A. J., Germans, T., Brouwer, W. P., Lubberink, M., Van Der Velden, J., Wilde, A. A. M., … Van Rossum, A. C. (2011). Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. European Journal of Heart Failure, 13(12), 1283–1289. https://doi.org/10.1093/eurjhf/hfr135

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free